ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Nucleotide-based Therapeutics Market Research Report 2025
Published Date: May 2025
|
Report Code: QYRE-Auto-11A16401
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Nucleotide based Therapeutics Market Research Report 2023
BUY CHAPTERS

Global Nucleotide-based Therapeutics Market Research Report 2025

Code: QYRE-Auto-11A16401
Report
May 2025
Pages:98
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Sarepta Therapeutics
Ionis Pharmaceuticals
Alnylam
Biogen
Nippon Shinyaku
SOBI
Novartis
BioNTech
Pfizer Inc
Moderna Therapeutics
Jazz Pharmaceuticals
CureVac
Regulus Therapeutics
ProQR
Secarna
Mina Therapeutics
Sylentis
Arrowhead
Silence Therapeutics
Dicerna

Nucleotide-based Therapeutics Market Size

The global market for Nucleotide-based Therapeutics was valued at US$ 12900 million in the year 2024 and is projected to reach a revised size of US$ 16590 million by 2031, growing at a CAGR of 3.7% during the forecast period.

Nucleotide-based Therapeutics Market

Nucleotide-based Therapeutics Market

Nucleotide-based therapeutics offer huge potential to specifically modulate cellular pathways in ways not previously possible. These therapies include all nucleic-acid-based approaches that work inside cells to affect gene expression – the genetic blueprint of disease – to ultimately change protein expression and potentially alter the course of disease.
The Nucleic Acid-Based Therapeutics Drug Market is driven by the promising potential of nucleic acid-based therapies in treating various genetic and acquired diseases, including genetic disorders, cancer, and infectious diseases. These innovative drugs utilize nucleic acids, such as DNA or RNA, to modify or regulate gene expression, correct genetic mutations, or target specific disease-associated genes. As the understanding of genomics and molecular biology advances, and personalized medicine gains traction, the demand for nucleic acid-based therapeutics continues to grow. Innovations in drug development, delivery systems, and gene editing technologies further contribute to market expansion. However, a significant challenge for this market is the need to address delivery and stability issues, ensure long-term safety and efficacy, and navigate regulatory complexities and patient acceptance. Overcoming technical and scientific hurdles, optimizing drug delivery methods, and addressing concerns about off-target effects are ongoing challenges. Additionally, the market faces competition from conventional therapies and the need for continuous research and development to unlock the full therapeutic potential of nucleic acid-based drugs. Striking a balance between providing safe, effective, and accessible nucleic acid-based therapeutics while addressing scientific and regulatory challenges is essential for the continued growth of the Nucleic Acid-Based Therapeutics Drug Market.
This report aims to provide a comprehensive presentation of the global market for Nucleotide-based Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Nucleotide-based Therapeutics.
The Nucleotide-based Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Nucleotide-based Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Nucleotide-based Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Nucleotide-based Therapeutics Market Report

Report Metric Details
Report Name Nucleotide-based Therapeutics Market
Accounted market size in year US$ 12900 million
Forecasted market size in 2031 US$ 16590 million
CAGR 3.7%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
Segment by Application
  • Neuromuscular Diseases
  • hATTR
  • COVID-19
  • Other
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Sarepta Therapeutics, Ionis Pharmaceuticals, Alnylam, Biogen, Nippon Shinyaku, Sobi, Novartis, BioNTech, Pfizer, Moderna Therapeutics, Jazz Pharmaceuticals, CureVac, Regulus Therapeutics, ProQR, Secarna, MiNA Therapeutics, Sylentis, Arrowhead, Silence Therapeutics, Dicerna
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Nucleotide-based Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Nucleotide-based Therapeutics Market growing?

Ans: The Nucleotide-based Therapeutics Market witnessing a CAGR of 3.7% during the forecast period 2025-2031.

What is the Nucleotide-based Therapeutics Market size in 2031?

Ans: The Nucleotide-based Therapeutics Market size in 2031 will be US$ 16590 million.

Who are the main players in the Nucleotide-based Therapeutics Market report?

Ans: The main players in the Nucleotide-based Therapeutics Market are Sarepta Therapeutics, Ionis Pharmaceuticals, Alnylam, Biogen, Nippon Shinyaku, Sobi, Novartis, BioNTech, Pfizer, Moderna Therapeutics, Jazz Pharmaceuticals, CureVac, Regulus Therapeutics, ProQR, Secarna, MiNA Therapeutics, Sylentis, Arrowhead, Silence Therapeutics, Dicerna

What are the Application segmentation covered in the Nucleotide-based Therapeutics Market report?

Ans: The Applications covered in the Nucleotide-based Therapeutics Market report are Neuromuscular Diseases, hATTR, COVID-19, Other

What are the Type segmentation covered in the Nucleotide-based Therapeutics Market report?

Ans: The Types covered in the Nucleotide-based Therapeutics Market report are Antisense Oligonucleotides (ASO), siRNA, mRNA

Recommended Reports

Gene Therapies

Oligonucleotide Drugs

RNA Therapeutics

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Nucleotide-based Therapeutics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Antisense Oligonucleotides (ASO)
1.2.3 siRNA
1.2.4 mRNA
1.3 Market by Application
1.3.1 Global Nucleotide-based Therapeutics Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Neuromuscular Diseases
1.3.3 hATTR
1.3.4 COVID-19
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Nucleotide-based Therapeutics Market Perspective (2020-2031)
2.2 Global Nucleotide-based Therapeutics Growth Trends by Region
2.2.1 Global Nucleotide-based Therapeutics Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Nucleotide-based Therapeutics Historic Market Size by Region (2020-2025)
2.2.3 Nucleotide-based Therapeutics Forecasted Market Size by Region (2026-2031)
2.3 Nucleotide-based Therapeutics Market Dynamics
2.3.1 Nucleotide-based Therapeutics Industry Trends
2.3.2 Nucleotide-based Therapeutics Market Drivers
2.3.3 Nucleotide-based Therapeutics Market Challenges
2.3.4 Nucleotide-based Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Nucleotide-based Therapeutics Players by Revenue
3.1.1 Global Top Nucleotide-based Therapeutics Players by Revenue (2020-2025)
3.1.2 Global Nucleotide-based Therapeutics Revenue Market Share by Players (2020-2025)
3.2 Global Nucleotide-based Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Nucleotide-based Therapeutics Revenue
3.4 Global Nucleotide-based Therapeutics Market Concentration Ratio
3.4.1 Global Nucleotide-based Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Nucleotide-based Therapeutics Revenue in 2024
3.5 Global Key Players of Nucleotide-based Therapeutics Head office and Area Served
3.6 Global Key Players of Nucleotide-based Therapeutics, Product and Application
3.7 Global Key Players of Nucleotide-based Therapeutics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Nucleotide-based Therapeutics Breakdown Data by Type
4.1 Global Nucleotide-based Therapeutics Historic Market Size by Type (2020-2025)
4.2 Global Nucleotide-based Therapeutics Forecasted Market Size by Type (2026-2031)
5 Nucleotide-based Therapeutics Breakdown Data by Application
5.1 Global Nucleotide-based Therapeutics Historic Market Size by Application (2020-2025)
5.2 Global Nucleotide-based Therapeutics Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Nucleotide-based Therapeutics Market Size (2020-2031)
6.2 North America Nucleotide-based Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Nucleotide-based Therapeutics Market Size by Country (2020-2025)
6.4 North America Nucleotide-based Therapeutics Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Nucleotide-based Therapeutics Market Size (2020-2031)
7.2 Europe Nucleotide-based Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Nucleotide-based Therapeutics Market Size by Country (2020-2025)
7.4 Europe Nucleotide-based Therapeutics Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Nucleotide-based Therapeutics Market Size (2020-2031)
8.2 Asia-Pacific Nucleotide-based Therapeutics Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Nucleotide-based Therapeutics Market Size by Region (2020-2025)
8.4 Asia-Pacific Nucleotide-based Therapeutics Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Nucleotide-based Therapeutics Market Size (2020-2031)
9.2 Latin America Nucleotide-based Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Nucleotide-based Therapeutics Market Size by Country (2020-2025)
9.4 Latin America Nucleotide-based Therapeutics Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Nucleotide-based Therapeutics Market Size (2020-2031)
10.2 Middle East & Africa Nucleotide-based Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Nucleotide-based Therapeutics Market Size by Country (2020-2025)
10.4 Middle East & Africa Nucleotide-based Therapeutics Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Sarepta Therapeutics
11.1.1 Sarepta Therapeutics Company Details
11.1.2 Sarepta Therapeutics Business Overview
11.1.3 Sarepta Therapeutics Nucleotide-based Therapeutics Introduction
11.1.4 Sarepta Therapeutics Revenue in Nucleotide-based Therapeutics Business (2020-2025)
11.1.5 Sarepta Therapeutics Recent Development
11.2 Ionis Pharmaceuticals
11.2.1 Ionis Pharmaceuticals Company Details
11.2.2 Ionis Pharmaceuticals Business Overview
11.2.3 Ionis Pharmaceuticals Nucleotide-based Therapeutics Introduction
11.2.4 Ionis Pharmaceuticals Revenue in Nucleotide-based Therapeutics Business (2020-2025)
11.2.5 Ionis Pharmaceuticals Recent Development
11.3 Alnylam
11.3.1 Alnylam Company Details
11.3.2 Alnylam Business Overview
11.3.3 Alnylam Nucleotide-based Therapeutics Introduction
11.3.4 Alnylam Revenue in Nucleotide-based Therapeutics Business (2020-2025)
11.3.5 Alnylam Recent Development
11.4 Biogen
11.4.1 Biogen Company Details
11.4.2 Biogen Business Overview
11.4.3 Biogen Nucleotide-based Therapeutics Introduction
11.4.4 Biogen Revenue in Nucleotide-based Therapeutics Business (2020-2025)
11.4.5 Biogen Recent Development
11.5 Nippon Shinyaku
11.5.1 Nippon Shinyaku Company Details
11.5.2 Nippon Shinyaku Business Overview
11.5.3 Nippon Shinyaku Nucleotide-based Therapeutics Introduction
11.5.4 Nippon Shinyaku Revenue in Nucleotide-based Therapeutics Business (2020-2025)
11.5.5 Nippon Shinyaku Recent Development
11.6 Sobi
11.6.1 Sobi Company Details
11.6.2 Sobi Business Overview
11.6.3 Sobi Nucleotide-based Therapeutics Introduction
11.6.4 Sobi Revenue in Nucleotide-based Therapeutics Business (2020-2025)
11.6.5 Sobi Recent Development
11.7 Novartis
11.7.1 Novartis Company Details
11.7.2 Novartis Business Overview
11.7.3 Novartis Nucleotide-based Therapeutics Introduction
11.7.4 Novartis Revenue in Nucleotide-based Therapeutics Business (2020-2025)
11.7.5 Novartis Recent Development
11.8 BioNTech
11.8.1 BioNTech Company Details
11.8.2 BioNTech Business Overview
11.8.3 BioNTech Nucleotide-based Therapeutics Introduction
11.8.4 BioNTech Revenue in Nucleotide-based Therapeutics Business (2020-2025)
11.8.5 BioNTech Recent Development
11.9 Pfizer
11.9.1 Pfizer Company Details
11.9.2 Pfizer Business Overview
11.9.3 Pfizer Nucleotide-based Therapeutics Introduction
11.9.4 Pfizer Revenue in Nucleotide-based Therapeutics Business (2020-2025)
11.9.5 Pfizer Recent Development
11.10 Moderna Therapeutics
11.10.1 Moderna Therapeutics Company Details
11.10.2 Moderna Therapeutics Business Overview
11.10.3 Moderna Therapeutics Nucleotide-based Therapeutics Introduction
11.10.4 Moderna Therapeutics Revenue in Nucleotide-based Therapeutics Business (2020-2025)
11.10.5 Moderna Therapeutics Recent Development
11.11 Jazz Pharmaceuticals
11.11.1 Jazz Pharmaceuticals Company Details
11.11.2 Jazz Pharmaceuticals Business Overview
11.11.3 Jazz Pharmaceuticals Nucleotide-based Therapeutics Introduction
11.11.4 Jazz Pharmaceuticals Revenue in Nucleotide-based Therapeutics Business (2020-2025)
11.11.5 Jazz Pharmaceuticals Recent Development
11.12 CureVac
11.12.1 CureVac Company Details
11.12.2 CureVac Business Overview
11.12.3 CureVac Nucleotide-based Therapeutics Introduction
11.12.4 CureVac Revenue in Nucleotide-based Therapeutics Business (2020-2025)
11.12.5 CureVac Recent Development
11.13 Regulus Therapeutics
11.13.1 Regulus Therapeutics Company Details
11.13.2 Regulus Therapeutics Business Overview
11.13.3 Regulus Therapeutics Nucleotide-based Therapeutics Introduction
11.13.4 Regulus Therapeutics Revenue in Nucleotide-based Therapeutics Business (2020-2025)
11.13.5 Regulus Therapeutics Recent Development
11.14 ProQR
11.14.1 ProQR Company Details
11.14.2 ProQR Business Overview
11.14.3 ProQR Nucleotide-based Therapeutics Introduction
11.14.4 ProQR Revenue in Nucleotide-based Therapeutics Business (2020-2025)
11.14.5 ProQR Recent Development
11.15 Secarna
11.15.1 Secarna Company Details
11.15.2 Secarna Business Overview
11.15.3 Secarna Nucleotide-based Therapeutics Introduction
11.15.4 Secarna Revenue in Nucleotide-based Therapeutics Business (2020-2025)
11.15.5 Secarna Recent Development
11.16 MiNA Therapeutics
11.16.1 MiNA Therapeutics Company Details
11.16.2 MiNA Therapeutics Business Overview
11.16.3 MiNA Therapeutics Nucleotide-based Therapeutics Introduction
11.16.4 MiNA Therapeutics Revenue in Nucleotide-based Therapeutics Business (2020-2025)
11.16.5 MiNA Therapeutics Recent Development
11.17 Sylentis
11.17.1 Sylentis Company Details
11.17.2 Sylentis Business Overview
11.17.3 Sylentis Nucleotide-based Therapeutics Introduction
11.17.4 Sylentis Revenue in Nucleotide-based Therapeutics Business (2020-2025)
11.17.5 Sylentis Recent Development
11.18 Arrowhead
11.18.1 Arrowhead Company Details
11.18.2 Arrowhead Business Overview
11.18.3 Arrowhead Nucleotide-based Therapeutics Introduction
11.18.4 Arrowhead Revenue in Nucleotide-based Therapeutics Business (2020-2025)
11.18.5 Arrowhead Recent Development
11.19 Silence Therapeutics
11.19.1 Silence Therapeutics Company Details
11.19.2 Silence Therapeutics Business Overview
11.19.3 Silence Therapeutics Nucleotide-based Therapeutics Introduction
11.19.4 Silence Therapeutics Revenue in Nucleotide-based Therapeutics Business (2020-2025)
11.19.5 Silence Therapeutics Recent Development
11.20 Dicerna
11.20.1 Dicerna Company Details
11.20.2 Dicerna Business Overview
11.20.3 Dicerna Nucleotide-based Therapeutics Introduction
11.20.4 Dicerna Revenue in Nucleotide-based Therapeutics Business (2020-2025)
11.20.5 Dicerna Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Sarepta Therapeutics
Ionis Pharmaceuticals
Alnylam
Biogen
Nippon Shinyaku
SOBI
Novartis
BioNTech
Pfizer Inc
Moderna Therapeutics
Jazz Pharmaceuticals
CureVac
Regulus Therapeutics
ProQR
Secarna
Mina Therapeutics
Sylentis
Arrowhead
Silence Therapeutics
Dicerna
List of Tables
 Table 1. Global Nucleotide-based Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Antisense Oligonucleotides (ASO)
 Table 3. Key Players of siRNA
 Table 4. Key Players of mRNA
 Table 5. Global Nucleotide-based Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 6. Global Nucleotide-based Therapeutics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 7. Global Nucleotide-based Therapeutics Market Size by Region (2020-2025) & (US$ Million)
 Table 8. Global Nucleotide-based Therapeutics Market Share by Region (2020-2025)
 Table 9. Global Nucleotide-based Therapeutics Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 10. Global Nucleotide-based Therapeutics Market Share by Region (2026-2031)
 Table 11. Nucleotide-based Therapeutics Market Trends
 Table 12. Nucleotide-based Therapeutics Market Drivers
 Table 13. Nucleotide-based Therapeutics Market Challenges
 Table 14. Nucleotide-based Therapeutics Market Restraints
 Table 15. Global Nucleotide-based Therapeutics Revenue by Players (2020-2025) & (US$ Million)
 Table 16. Global Nucleotide-based Therapeutics Market Share by Players (2020-2025)
 Table 17. Global Top Nucleotide-based Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nucleotide-based Therapeutics as of 2024)
 Table 18. Ranking of Global Top Nucleotide-based Therapeutics Companies by Revenue (US$ Million) in 2024
 Table 19. Global 5 Largest Players Market Share by Nucleotide-based Therapeutics Revenue (CR5 and HHI) & (2020-2025)
 Table 20. Global Key Players of Nucleotide-based Therapeutics, Headquarters and Area Served
 Table 21. Global Key Players of Nucleotide-based Therapeutics, Product and Application
 Table 22. Global Key Players of Nucleotide-based Therapeutics, Date of Enter into This Industry
 Table 23. Mergers & Acquisitions, Expansion Plans
 Table 24. Global Nucleotide-based Therapeutics Market Size by Type (2020-2025) & (US$ Million)
 Table 25. Global Nucleotide-based Therapeutics Revenue Market Share by Type (2020-2025)
 Table 26. Global Nucleotide-based Therapeutics Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 27. Global Nucleotide-based Therapeutics Revenue Market Share by Type (2026-2031)
 Table 28. Global Nucleotide-based Therapeutics Market Size by Application (2020-2025) & (US$ Million)
 Table 29. Global Nucleotide-based Therapeutics Revenue Market Share by Application (2020-2025)
 Table 30. Global Nucleotide-based Therapeutics Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 31. Global Nucleotide-based Therapeutics Revenue Market Share by Application (2026-2031)
 Table 32. North America Nucleotide-based Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 33. North America Nucleotide-based Therapeutics Market Size by Country (2020-2025) & (US$ Million)
 Table 34. North America Nucleotide-based Therapeutics Market Size by Country (2026-2031) & (US$ Million)
 Table 35. Europe Nucleotide-based Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 36. Europe Nucleotide-based Therapeutics Market Size by Country (2020-2025) & (US$ Million)
 Table 37. Europe Nucleotide-based Therapeutics Market Size by Country (2026-2031) & (US$ Million)
 Table 38. Asia-Pacific Nucleotide-based Therapeutics Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 39. Asia-Pacific Nucleotide-based Therapeutics Market Size by Region (2020-2025) & (US$ Million)
 Table 40. Asia-Pacific Nucleotide-based Therapeutics Market Size by Region (2026-2031) & (US$ Million)
 Table 41. Latin America Nucleotide-based Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 42. Latin America Nucleotide-based Therapeutics Market Size by Country (2020-2025) & (US$ Million)
 Table 43. Latin America Nucleotide-based Therapeutics Market Size by Country (2026-2031) & (US$ Million)
 Table 44. Middle East & Africa Nucleotide-based Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 45. Middle East & Africa Nucleotide-based Therapeutics Market Size by Country (2020-2025) & (US$ Million)
 Table 46. Middle East & Africa Nucleotide-based Therapeutics Market Size by Country (2026-2031) & (US$ Million)
 Table 47. Sarepta Therapeutics Company Details
 Table 48. Sarepta Therapeutics Business Overview
 Table 49. Sarepta Therapeutics Nucleotide-based Therapeutics Product
 Table 50. Sarepta Therapeutics Revenue in Nucleotide-based Therapeutics Business (2020-2025) & (US$ Million)
 Table 51. Sarepta Therapeutics Recent Development
 Table 52. Ionis Pharmaceuticals Company Details
 Table 53. Ionis Pharmaceuticals Business Overview
 Table 54. Ionis Pharmaceuticals Nucleotide-based Therapeutics Product
 Table 55. Ionis Pharmaceuticals Revenue in Nucleotide-based Therapeutics Business (2020-2025) & (US$ Million)
 Table 56. Ionis Pharmaceuticals Recent Development
 Table 57. Alnylam Company Details
 Table 58. Alnylam Business Overview
 Table 59. Alnylam Nucleotide-based Therapeutics Product
 Table 60. Alnylam Revenue in Nucleotide-based Therapeutics Business (2020-2025) & (US$ Million)
 Table 61. Alnylam Recent Development
 Table 62. Biogen Company Details
 Table 63. Biogen Business Overview
 Table 64. Biogen Nucleotide-based Therapeutics Product
 Table 65. Biogen Revenue in Nucleotide-based Therapeutics Business (2020-2025) & (US$ Million)
 Table 66. Biogen Recent Development
 Table 67. Nippon Shinyaku Company Details
 Table 68. Nippon Shinyaku Business Overview
 Table 69. Nippon Shinyaku Nucleotide-based Therapeutics Product
 Table 70. Nippon Shinyaku Revenue in Nucleotide-based Therapeutics Business (2020-2025) & (US$ Million)
 Table 71. Nippon Shinyaku Recent Development
 Table 72. Sobi Company Details
 Table 73. Sobi Business Overview
 Table 74. Sobi Nucleotide-based Therapeutics Product
 Table 75. Sobi Revenue in Nucleotide-based Therapeutics Business (2020-2025) & (US$ Million)
 Table 76. Sobi Recent Development
 Table 77. Novartis Company Details
 Table 78. Novartis Business Overview
 Table 79. Novartis Nucleotide-based Therapeutics Product
 Table 80. Novartis Revenue in Nucleotide-based Therapeutics Business (2020-2025) & (US$ Million)
 Table 81. Novartis Recent Development
 Table 82. BioNTech Company Details
 Table 83. BioNTech Business Overview
 Table 84. BioNTech Nucleotide-based Therapeutics Product
 Table 85. BioNTech Revenue in Nucleotide-based Therapeutics Business (2020-2025) & (US$ Million)
 Table 86. BioNTech Recent Development
 Table 87. Pfizer Company Details
 Table 88. Pfizer Business Overview
 Table 89. Pfizer Nucleotide-based Therapeutics Product
 Table 90. Pfizer Revenue in Nucleotide-based Therapeutics Business (2020-2025) & (US$ Million)
 Table 91. Pfizer Recent Development
 Table 92. Moderna Therapeutics Company Details
 Table 93. Moderna Therapeutics Business Overview
 Table 94. Moderna Therapeutics Nucleotide-based Therapeutics Product
 Table 95. Moderna Therapeutics Revenue in Nucleotide-based Therapeutics Business (2020-2025) & (US$ Million)
 Table 96. Moderna Therapeutics Recent Development
 Table 97. Jazz Pharmaceuticals Company Details
 Table 98. Jazz Pharmaceuticals Business Overview
 Table 99. Jazz Pharmaceuticals Nucleotide-based Therapeutics Product
 Table 100. Jazz Pharmaceuticals Revenue in Nucleotide-based Therapeutics Business (2020-2025) & (US$ Million)
 Table 101. Jazz Pharmaceuticals Recent Development
 Table 102. CureVac Company Details
 Table 103. CureVac Business Overview
 Table 104. CureVac Nucleotide-based Therapeutics Product
 Table 105. CureVac Revenue in Nucleotide-based Therapeutics Business (2020-2025) & (US$ Million)
 Table 106. CureVac Recent Development
 Table 107. Regulus Therapeutics Company Details
 Table 108. Regulus Therapeutics Business Overview
 Table 109. Regulus Therapeutics Nucleotide-based Therapeutics Product
 Table 110. Regulus Therapeutics Revenue in Nucleotide-based Therapeutics Business (2020-2025) & (US$ Million)
 Table 111. Regulus Therapeutics Recent Development
 Table 112. ProQR Company Details
 Table 113. ProQR Business Overview
 Table 114. ProQR Nucleotide-based Therapeutics Product
 Table 115. ProQR Revenue in Nucleotide-based Therapeutics Business (2020-2025) & (US$ Million)
 Table 116. ProQR Recent Development
 Table 117. Secarna Company Details
 Table 118. Secarna Business Overview
 Table 119. Secarna Nucleotide-based Therapeutics Product
 Table 120. Secarna Revenue in Nucleotide-based Therapeutics Business (2020-2025) & (US$ Million)
 Table 121. Secarna Recent Development
 Table 122. MiNA Therapeutics Company Details
 Table 123. MiNA Therapeutics Business Overview
 Table 124. MiNA Therapeutics Nucleotide-based Therapeutics Product
 Table 125. MiNA Therapeutics Revenue in Nucleotide-based Therapeutics Business (2020-2025) & (US$ Million)
 Table 126. MiNA Therapeutics Recent Development
 Table 127. Sylentis Company Details
 Table 128. Sylentis Business Overview
 Table 129. Sylentis Nucleotide-based Therapeutics Product
 Table 130. Sylentis Revenue in Nucleotide-based Therapeutics Business (2020-2025) & (US$ Million)
 Table 131. Sylentis Recent Development
 Table 132. Arrowhead Company Details
 Table 133. Arrowhead Business Overview
 Table 134. Arrowhead Nucleotide-based Therapeutics Product
 Table 135. Arrowhead Revenue in Nucleotide-based Therapeutics Business (2020-2025) & (US$ Million)
 Table 136. Arrowhead Recent Development
 Table 137. Silence Therapeutics Company Details
 Table 138. Silence Therapeutics Business Overview
 Table 139. Silence Therapeutics Nucleotide-based Therapeutics Product
 Table 140. Silence Therapeutics Revenue in Nucleotide-based Therapeutics Business (2020-2025) & (US$ Million)
 Table 141. Silence Therapeutics Recent Development
 Table 142. Dicerna Company Details
 Table 143. Dicerna Business Overview
 Table 144. Dicerna Nucleotide-based Therapeutics Product
 Table 145. Dicerna Revenue in Nucleotide-based Therapeutics Business (2020-2025) & (US$ Million)
 Table 146. Dicerna Recent Development
 Table 147. Research Programs/Design for This Report
 Table 148. Key Data Information from Secondary Sources
 Table 149. Key Data Information from Primary Sources
 Table 150. Authors List of This Report


List of Figures
 Figure 1. Nucleotide-based Therapeutics Picture
 Figure 2. Global Nucleotide-based Therapeutics Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Nucleotide-based Therapeutics Market Share by Type: 2024 VS 2031
 Figure 4. Antisense Oligonucleotides (ASO) Features
 Figure 5. siRNA Features
 Figure 6. mRNA Features
 Figure 7. Global Nucleotide-based Therapeutics Market Size by Application (2020-2031) & (US$ Million)
 Figure 8. Global Nucleotide-based Therapeutics Market Share by Application: 2024 VS 2031
 Figure 9. Neuromuscular Diseases Case Studies
 Figure 10. hATTR Case Studies
 Figure 11. COVID-19 Case Studies
 Figure 12. Other Case Studies
 Figure 13. Nucleotide-based Therapeutics Report Years Considered
 Figure 14. Global Nucleotide-based Therapeutics Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 15. Global Nucleotide-based Therapeutics Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 16. Global Nucleotide-based Therapeutics Market Share by Region: 2024 VS 2031
 Figure 17. Global Nucleotide-based Therapeutics Market Share by Players in 2024
 Figure 18. Global Top Nucleotide-based Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nucleotide-based Therapeutics as of 2024)
 Figure 19. The Top 10 and 5 Players Market Share by Nucleotide-based Therapeutics Revenue in 2024
 Figure 20. North America Nucleotide-based Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 21. North America Nucleotide-based Therapeutics Market Share by Country (2020-2031)
 Figure 22. United States Nucleotide-based Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 23. Canada Nucleotide-based Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. Europe Nucleotide-based Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. Europe Nucleotide-based Therapeutics Market Share by Country (2020-2031)
 Figure 26. Germany Nucleotide-based Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. France Nucleotide-based Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. U.K. Nucleotide-based Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Italy Nucleotide-based Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Russia Nucleotide-based Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Nordic Countries Nucleotide-based Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Asia-Pacific Nucleotide-based Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. Asia-Pacific Nucleotide-based Therapeutics Market Share by Region (2020-2031)
 Figure 34. China Nucleotide-based Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. Japan Nucleotide-based Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. South Korea Nucleotide-based Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. Southeast Asia Nucleotide-based Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. India Nucleotide-based Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Australia Nucleotide-based Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Latin America Nucleotide-based Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Latin America Nucleotide-based Therapeutics Market Share by Country (2020-2031)
 Figure 42. Mexico Nucleotide-based Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Brazil Nucleotide-based Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Middle East & Africa Nucleotide-based Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Middle East & Africa Nucleotide-based Therapeutics Market Share by Country (2020-2031)
 Figure 46. Turkey Nucleotide-based Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. Saudi Arabia Nucleotide-based Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 48. UAE Nucleotide-based Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 49. Sarepta Therapeutics Revenue Growth Rate in Nucleotide-based Therapeutics Business (2020-2025)
 Figure 50. Ionis Pharmaceuticals Revenue Growth Rate in Nucleotide-based Therapeutics Business (2020-2025)
 Figure 51. Alnylam Revenue Growth Rate in Nucleotide-based Therapeutics Business (2020-2025)
 Figure 52. Biogen Revenue Growth Rate in Nucleotide-based Therapeutics Business (2020-2025)
 Figure 53. Nippon Shinyaku Revenue Growth Rate in Nucleotide-based Therapeutics Business (2020-2025)
 Figure 54. Sobi Revenue Growth Rate in Nucleotide-based Therapeutics Business (2020-2025)
 Figure 55. Novartis Revenue Growth Rate in Nucleotide-based Therapeutics Business (2020-2025)
 Figure 56. BioNTech Revenue Growth Rate in Nucleotide-based Therapeutics Business (2020-2025)
 Figure 57. Pfizer Revenue Growth Rate in Nucleotide-based Therapeutics Business (2020-2025)
 Figure 58. Moderna Therapeutics Revenue Growth Rate in Nucleotide-based Therapeutics Business (2020-2025)
 Figure 59. Jazz Pharmaceuticals Revenue Growth Rate in Nucleotide-based Therapeutics Business (2020-2025)
 Figure 60. CureVac Revenue Growth Rate in Nucleotide-based Therapeutics Business (2020-2025)
 Figure 61. Regulus Therapeutics Revenue Growth Rate in Nucleotide-based Therapeutics Business (2020-2025)
 Figure 62. ProQR Revenue Growth Rate in Nucleotide-based Therapeutics Business (2020-2025)
 Figure 63. Secarna Revenue Growth Rate in Nucleotide-based Therapeutics Business (2020-2025)
 Figure 64. MiNA Therapeutics Revenue Growth Rate in Nucleotide-based Therapeutics Business (2020-2025)
 Figure 65. Sylentis Revenue Growth Rate in Nucleotide-based Therapeutics Business (2020-2025)
 Figure 66. Arrowhead Revenue Growth Rate in Nucleotide-based Therapeutics Business (2020-2025)
 Figure 67. Silence Therapeutics Revenue Growth Rate in Nucleotide-based Therapeutics Business (2020-2025)
 Figure 68. Dicerna Revenue Growth Rate in Nucleotide-based Therapeutics Business (2020-2025)
 Figure 69. Bottom-up and Top-down Approaches for This Report
 Figure 70. Data Triangulation
 Figure 71. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Accenture

SIMILAR REPORTS

Global Nucleic Acid based Therapy Market Research Report 2024
Global Nucleic Acid Based Gene Therapeutics Market Research Report 2024
Global Nucleic acid based Therapeutics Drug Market Research Report 2024
Global Nucleic Acid Therapeutic Market Research Report 2024
Global RNA based Therapeutics Drug Market Research Report 2024
Global Nucleic Acid Based Gene Therapy Market Research Report 2025
Global Oligonucleotide based Therapy Medicinal Product Market Research Report 2024
Oligonucleotide Therapeutics Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global RNA Therapeutics Market Research Report 2024
Global Nucleic Acid Drugs Market Research Report 2025
Global Oligonucleotide Therapy based Drug Market Research Report 2024
Antisense and RNAi Therapeutics Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Gene Therapies for Cancer Treatment Market Research Report 2024
Global Nucleotide Market Research Report 2024
Global RNA Interference RNAi Based Therapeutics Market Research Report 2024
Global Nucleic Acid Medicine Market Research Report 2025
Global Oligonucleotide Therapeutics Market Research Report 2024
Oligonucleotide based Therapies Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Oligonucleotide Drug Delivery Market Research Report 2024
Global Small Nucleic Acid Based Drug Market Research Report 2025
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions